Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-Gna13CA
- Development stage
- Preclinical
- Lead developer
- Tulane University
- Modality
- Gene Therapies
- Administration
- Intraarticular
01
Overview
AAV-Gna13CA is an adeno-associated virus (AAV)-based gene therapy designed to locally overexpress a constitutively active form of the guanine nucleotide-binding protein subunit alpha-13 (Gα13, encoded by the Gna13 gene). Developed by researchers at Tulane University, AAV-Gna13CA is being investigated for the treatment of rheumatoid arthritis (RA). Gα13 acts as a master negative endogenous regulator of macrophage-mediated inflammation and osteoclastogenesis. By delivering the constitutively active Gna13CA, the therapy suppresses the Gα13-TLR-NF-κB signaling pathway, thereby reducing synovial inflammation, immune cell infiltration, and pathological bone and cartilage destruction in preclinical models of rheumatoid arthritis.
- Other names
- AAV-Gna13(CA)AAV-Gα13CA
02
Targets
GNA13 (Gα13)
Beyond the preview
Go deeper on AAV-Gna13CA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-Gna13CA.